Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTEN shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous, Ophthalmic, Intravitreal, Inhalation, Oral
01
Overview
PTEN shRNA is a short hairpin RNA designed to silence the expression of the Phosphatase and tensin homolog (PTEN) gene through RNA interference (RNAi). PTEN is a critical tumor suppressor that acts as a phosphatase to dephosphorylate PIP3, thereby negatively regulating the PI3K/AKT/mTOR signaling pathway. In oncological research, PTEN shRNA is frequently employed—often delivered via lentiviral or adenoviral vectors—to model the loss of PTEN function observed in various cancers, including melanoma, prostate cancer, and glioblastoma. Knockdown of PTEN leads to constitutive activation of pro-survival and proliferative pathways; for instance, research indicates that PTEN depletion in melanocytes can upregulate EPAC-RAP1 signaling, facilitating malignant transformation and senescence escape.
- Other names
- PTEN-KDPTEN short hairpin RNA
02
Targets
PTEN (Phosphatase and tensin homolog deleted on chromosome ten)
Beyond the preview
Go deeper on PTEN shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTEN shRNA.